ArticleJournal of controlled release : official journal of the Controlled Release Society2014
Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Development and Characterization of a Stable Oil-in-Water Nanoemulsion Using Impingement Jet Mixing and Lyophilization Techniques.Pharmaceutics · 2026Article
- Design and immunogenicity of a recombinant Saccharomyces boulardii secreting the P2-VP8 subunit rotavirus vaccine.Scientific reports · 2026Article
- Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.Vaccines · 2024Review
- Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine.Heliyon · 2023Article
- An RNA-Based Vaccine Platform for Use againstVaccines · 2023Article
- Ionizing Radiation Technologies for Vaccine Development - A Mini Review.Frontiers in immunology · 2022Review
- Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.Frontiers in drug delivery · 2022Article
- Pathological and protective roles of dendritic cells inFrontiers in cellular and infection microbiology · 2022Review
- Article
- Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery.Vaccine · 2021Article
- Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray drying.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Article
- Development of thermostable vaccine adjuvants.Expert review of vaccines · 2021Review
- Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate.International journal of pharmaceutics · 2021Article
- Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model.Frontiers in pharmacology · 2021Article
- Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.PloS one · 2021Article
- Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic Response.Pharmaceuticals (Basel, Switzerland) · 2020Article
- The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01.Malaria journal · 2020Article
- Correlates of GLA family adjuvants' activities.Seminars in immunology · 2018Review
- Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review.Iranian journal of basic medical sciences · 2018Review
- Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine forNPJ vaccines · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Next-generation rationally-designed vaccine adjuvants represent a significant breakthrough to enable development of vaccines against challenging diseases including tuberculosis, HIV, and malaria. New vaccine candidates often require maintenance of a cold-chain process to ensure long-term stability and separate vials to enable bedside mixing of antigen and adjuvant. This presents a significant financial and technological barrier to worldwide implementation of such vaccines. Herein we describe the development and characterization of a tuberculosis vaccine comprised of both antigen and adjuvant components that are stable in a single vial at sustained elevated temperatures. Further this vaccine retains the ability to elicit both antibody and TH1 responses against the vaccine antigen and protect against experimental challenge with Mycobacterium tuberculosis. These results represent a significant breakthrough in the development of vaccine candidates that can be implemented throughout the world without being hampered by the necessity of a continuous cold chain or separate adjuvant and antigen vials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.